Viatris Inc. (VTRS)

$13.25

+0.12

(+0.91%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $13.11
    $13.32
    $13.25
    downward going graph

    1.09%

    Downside

    Day's Volatility :1.61%

    Upside

    0.53%

    downward going graph
  • $9.08
    $13.62
    $13.25
    downward going graph

    31.47%

    Downside

    52 Weeks Volatility :33.32%

    Upside

    2.7%

    downward going graph

Returns

PeriodViatris Inc.Sector (Health Care)S&P500
3 Months
12.03%
-7.6%
5.3%
6 Months
19.8%
-2.3%
11.2%
1 Year
39.98%
10.1%
30.4%
3 Years
0.08%
7.5%
26.0%

Highlights

Market Capitalization
15.1B
Book Value
$16.58
Dividend Share
0.48
Dividend Yield
3.69%
Earnings Per Share (EPS)
-0.71
PEG Ratio
0.08
Wall Street Target Price
13.084
Profit Margin
-5.87%
Operating Margin TTM
13.88%
Return On Assets TTM
2.48%
Return On Equity TTM
-4.34%
Revenue TTM
15.0B
Revenue Per Share TTM
12.59
Quarterly Revenue Growth YOY
-4.8%
Gross Profit TTM
7.0B
EBITDA
4.6B
Diluted Eps TTM
-0.71
Quarterly Earnings Growth YOY
-0.71
EPS Estimate Current Year
2.67
EPS Estimate Next Year
2.67
EPS Estimate Current Quarter
0.68
EPS Estimate Next Quarter
0.63

Analyst Recommendation

Hold
    7%Buy
    57%Hold
    35%Sell
Based on 14 Wall street analysts offering stock ratings for Viatris Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
8
8
8
Sell
5
5
5

Analyst Forecast

What analysts predicted

Downside of 1.25%

Current $13.25
Target $13.08

Company Financials

FY18Y/Y Change
Revenue
11.4B
↓ 3.98%
Net Income
352.5M
↓ 49.35%
Net Profit Margin
3.08%
↓ 2.76%
FY19Y/Y Change
Revenue
11.5B
↑ 0.58%
Net Income
16.8M
↓ 95.23%
Net Profit Margin
0.15%
↓ 2.93%
FY20Y/Y Change
Revenue
11.9B
↑ 3.87%
Net Income
-669.9M
↓ 4087.5%
Net Profit Margin
-5.61%
↓ 5.76%
FY21Y/Y Change
Revenue
17.9B
↑ 49.73%
Net Income
-1.3B
↑ 89.45%
Net Profit Margin
-7.1%
↓ 1.49%
FY22Y/Y Change
Revenue
16.3B
↓ 9.08%
Net Income
2.1B
↓ 263.79%
Net Profit Margin
12.78%
↑ 19.88%
FY23Y/Y Change
Revenue
15.4B
↓ 5.14%
Net Income
54.7M
↓ 97.37%
Net Profit Margin
0.35%
↓ 12.43%
Q2 FY23Q/Q Change
Revenue
3.9B
↑ 5.08%
Net Income
264.0M
↑ 17.49%
Net Profit Margin
6.74%
↑ 0.71%
Q3 FY23Q/Q Change
Revenue
3.9B
↑ 0.59%
Net Income
331.6M
↑ 25.61%
Net Profit Margin
8.41%
↑ 1.67%
Q4 FY23Q/Q Change
Revenue
3.8B
↓ 2.98%
Net Income
-765.6M
↓ 330.88%
Net Profit Margin
-20.02%
↓ 28.43%
Q1 FY24Q/Q Change
Revenue
3.7B
↓ 4.21%
Net Income
113.9M
↓ 114.88%
Net Profit Margin
3.11%
↑ 23.13%
Q2 FY24Q/Q Change
Revenue
3.8B
↑ 3.64%
Net Income
-326.4M
↓ 386.57%
Net Profit Margin
-8.6%
↓ 11.71%
Q3 FY24Q/Q Change
Revenue
3.7B
↓ 1.54%
Net Income
94.8M
↓ 129.04%
Net Profit Margin
2.54%
↑ 11.14%
FY18Y/Y Change
Total Assets
32.7B
↓ 8.58%
Total Liabilities
20.6B
↓ 8.58%
FY19Y/Y Change
Total Assets
31.3B
↓ 4.52%
Total Liabilities
19.4B
↓ 5.82%
FY20Y/Y Change
Total Assets
61.6B
↑ 96.93%
Total Liabilities
38.6B
↑ 99.25%
FY21Y/Y Change
Total Assets
54.8B
↓ 10.9%
Total Liabilities
34.4B
↓ 11.01%
FY22Y/Y Change
Total Assets
50.0B
↓ 8.79%
Total Liabilities
28.9B
↓ 15.72%
FY23Y/Y Change
Total Assets
47.7B
↓ 4.67%
Total Liabilities
27.2B
↓ 5.98%
Q2 FY23Q/Q Change
Total Assets
48.7B
↓ 1.21%
Total Liabilities
27.9B
↓ 1.8%
Q3 FY23Q/Q Change
Total Assets
48.7B
↑ 0.1%
Total Liabilities
27.9B
↑ 0.09%
Q4 FY23Q/Q Change
Total Assets
47.7B
↓ 2.17%
Total Liabilities
27.2B
↓ 2.36%
Q1 FY24Q/Q Change
Total Assets
47.3B
↓ 0.72%
Total Liabilities
27.3B
↑ 0.41%
Q2 FY24Q/Q Change
Total Assets
45.3B
↓ 4.25%
Total Liabilities
25.8B
↓ 5.56%
Q3 FY24Q/Q Change
Total Assets
44.8B
↓ 1.27%
Total Liabilities
25.0B
↓ 3.29%
FY18Y/Y Change
Operating Cash Flow
2.3B
↑ 13.41%
Investing Cash Flow
-1.2B
↑ 23.97%
Financing Cash Flow
-1.1B
↓ 42.37%
FY19Y/Y Change
Operating Cash Flow
1.8B
↓ 22.97%
Investing Cash Flow
-525.4M
↓ 56.59%
Financing Cash Flow
-1.2B
↑ 7.16%
FY20Y/Y Change
Operating Cash Flow
1.2B
↓ 31.71%
Investing Cash Flow
-301.1M
↓ 42.69%
Financing Cash Flow
-605.7M
↓ 48.19%
FY21Y/Y Change
Operating Cash Flow
3.0B
↑ 144.92%
Investing Cash Flow
-117.8M
↓ 60.88%
Financing Cash Flow
-3.0B
↑ 397.28%
FY22Y/Y Change
Operating Cash Flow
3.0B
↓ 2.13%
Investing Cash Flow
1.5B
↓ 1390.75%
Financing Cash Flow
-3.9B
↑ 28.75%
Q2 FY23Q/Q Change
Operating Cash Flow
514.9M
↓ 46.98%
Investing Cash Flow
-76.6M
↓ 89.78%
Financing Cash Flow
-303.5M
↓ 68.86%
Q3 FY23Q/Q Change
Operating Cash Flow
834.1M
↑ 61.99%
Investing Cash Flow
-53.8M
↓ 29.77%
Financing Cash Flow
-97.6M
↓ 67.84%

Technicals Summary

Sell

Neutral

Buy

Viatris Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Viatris Inc.
Viatris Inc.
13.48%
19.8%
39.98%
0.08%
-19.65%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.76%
-12.28%
12.48%
43.36%
8.39%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-5.01%
11.27%
13.94%
27.94%
27.94%
Zoetis Inc.
Zoetis Inc.
-7.27%
1.67%
-1.71%
-21.69%
46.12%
Catalent, Inc.
Catalent, Inc.
-1.96%
7.35%
48.09%
-54.14%
14.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Viatris Inc.
Viatris Inc.
224.4
NA
0.08
2.67
-0.04
0.02
0.04
16.58
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
31.77
32.88
0.28
6.54
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.58
28.73
1.69
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
33.0
33.0
2.46
5.87
0.47
0.15
0.01
11.59
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.95
0.2
-0.11
0.0
NA
19.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Viatris Inc.
Viatris Inc.
Hold
$15.1B
-19.65%
224.4
-5.87%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.1B
8.39%
31.77
17.21%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$42.6B
27.94%
28.58
10.75%
Zoetis Inc.
Zoetis Inc.
Buy
$79.2B
46.12%
33.0
26.55%
Catalent, Inc.
Catalent, Inc.
Hold
$10.7B
14.45%
211.02
-9.34%

Insights on Viatris Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.79B → 3.73B (in $), with an average decrease of 1.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -326.4M → 94.8M (in $), with an average increase of 444.3% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 48.1% return, outperforming this stock by 8.1%

Institutional Holdings

  • Vanguard Group Inc

    11.76%

  • BlackRock Inc

    7.76%

  • State Street Corp

    5.20%

  • Davis Selected Advisers

    4.82%

  • T. Rowe Price Associates, Inc.

    4.76%

  • Pacer Advisors, INC.

    3.21%

Corporate Announcements

  • Viatris Inc. Dividends March,2024

    In the quarter ending March,2024. Viatris Inc. has declared dividend of $0.12

    Read More

Company Information

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.

Organization
Viatris Inc.
Employees
32000
CEO
Mr. Brian S. Roman
Industry
Health Technology

FAQs